Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response.

Adult Allergens / immunology Double-Blind Method Female Humans Immune Tolerance Immunity, Innate Interleukin-10 / metabolism Janus Kinases / metabolism Lectins, C-Type / metabolism Lymphocytes / immunology Male Middle Aged Placebo Effect Poaceae / immunology Pollen / immunology Receptors, Immunologic / metabolism Rhinitis, Allergic, Seasonal / immunology STAT Transcription Factors / metabolism Signal Transduction Sublingual Immunotherapy / methods Th2 Cells / immunology Treatment Outcome Vitamin A / metabolism Young Adult
IL-10 KLRG1 allergen specific immunotherapy allergy group 2 innate lymphoid cells immunotherapy innate lymphoid cells plasticity retinoic acid

Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
09 02 2021
Historique:
received: 07 05 2020
revised: 04 11 2020
accepted: 17 12 2020
pubmed: 16 1 2021
medline: 8 9 2021
entrez: 15 1 2021
Statut: ppublish

Résumé

The role of innate immune cells in allergen immunotherapy that confers immune tolerance to the sensitizing allergen is unclear. Here, we report a role of interleukin-10-producing type 2 innate lymphoid cells (IL-10

Identifiants

DOI: 10.1016/j.immuni.2020.12.013 PMID: 33450188
pubmed: 33450188
pii: S1074-7613(20)30541-0
doi: 10.1016/j.immuni.2020.12.013
pii:
doi:

Substances chimiques

Allergens 0
KLRG1 protein, human 0
Lectins, C-Type 0
Receptors, Immunologic 0
STAT Transcription Factors 0
Vitamin A 11103-57-4
Interleukin-10 130068-27-8
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

291-307.e7

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests K.G., J.A.L., U.S., M.M.L., R.C.Y.L., S.M.B., B.A.H., G.V.-N., O.H., G.M., F.Q.H., O.F., M.L.A., S.J.H.V., A.-H.M.v.d.Z., C.M.v.D., and W.F. report no conflicts of interest. E.H.S.-K. has received travel grants from ALK-Abello. Stephen Durham has received lecture fees and research funds from ALK, Denmark, manufacturer of grass allergen tablets used for sublingual immunotherapy. M.O. is a consultant for Hycor Biomedical and a co-founder of Tolerogenics SARL. Unrelated intellectual property of M.O. and the Luxembourg Institute of Health has been licensed to Tolerogenics. H.S. is a consultant for GSK for which he receives an honorarium. M.H.S. reports research grants from Immune Tolerance Network, Medical Research Council, Allergy Therapeutics, and LETI Laboratorios and lecture fees from Allergy Therapeutics and ALK.

Auteurs

Korneliusz Golebski (K)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Janice A Layhadi (JA)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK; NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, Imperial College London, London, UK.

Umit Sahiner (U)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.

Esther H Steveling-Klein (EH)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK; Department of Dermatology, Allergy Unit, University Hospital Basel, Basel, Switzerland.

Madison M Lenormand (MM)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK; NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, Imperial College London, London, UK.

Rachael C Y Li (RCY)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK; NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, Imperial College London, London, UK.

Suzanne M Bal (SM)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Balthasar A Heesters (BA)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Gemma Vilà-Nadal (G)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.

Oliver Hunewald (O)

Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, 4354 Esch-sur-Alzette, Luxembourg.

Guillem Montamat (G)

Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, 4354 Esch-sur-Alzette, Luxembourg; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Feng Q He (FQ)

Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, 4354 Esch-sur-Alzette, Luxembourg; Institute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.

Markus Ollert (M)

Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, 4354 Esch-sur-Alzette, Luxembourg; Department of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.

Oleksandra Fedina (O)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.

Mongkol Lao-Araya (M)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.

Susanne J H Vijverberg (SJH)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Anke-Hilse Maitland-van der Zee (AH)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Cornelis M van Drunen (CM)

Department of Otorhinolaryngology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Wytske J Fokkens (WJ)

Department of Otorhinolaryngology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Stephen R Durham (SR)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK; NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, Imperial College London, London, UK.

Hergen Spits (H)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: hergen.spits@amsterdamumc.nl.

Mohamed H Shamji (MH)

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK; NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, Imperial College London, London, UK. Electronic address: m.shamji@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Allergènes › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méthode en double aveugle › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Tolérance immunitaire › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité innée › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-10 › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Janus kinases › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lectines › Lectines de type C › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Modificateur d'effet épidémiologique › Effet placebo › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Poaceae › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Structures de plante › Parties aériennes de plante › Sommités fleuries › Fleurs › Cellules germinales de plante › Pollen › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Hypersensibilité respiratoire › Rhinite allergique › Rhinite allergique saisonnière › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription STAT › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Désensibilisation immunologique › Immunothérapie sublinguale › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T auxiliaires › Lymphocytes auxiliaires Th2 › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Facteurs biologiques › Pigments biologiques › Caroténoïdes › Rétinoïdes › Rétinol › Induction of IL-10-producing type 2 innate...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Induction of IL-10-producing type 2 innate...